Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator

Thrombosis and Haemostasis

Volumn 80, Issue 5, 1998, Pages 822-828

  Horn, Ivo R ^a   Van Den Berg, Birgit M M ^a   Moestrup, Søren K ^b   Pannekoek, Hans ^a   Van Zonneveld, Anton Jan ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AARHUS UNIVERSITY   (Denmark)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSINE; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING SITE; CELL STRAIN COS1; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; INTERNALIZATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR AFFINITY;

EID: 0031743824     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615365     Document Type: Article

References (39)

1. Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995; 74: 167-71.
2. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995; 74: 429-36.
3. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-76.
4. Bounameaux H, Stassen JM, Seghers C, Collen D. Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits. Blood 1986; 67: 1493-7.
5. Narita M, Bu G, Herz J, Schwartz AL. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 1995; 96: 1164-8.
6. Otter M, Barrett-Bergshoeff MM, Rijken DC. Binding of tissue-type plasminogen by the mannose receptor. J Biol Chem 1991; 266: 13931-5.
7. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992; 269: 375-82.
8. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). [Review]. Annu Rev Biochem 1994; 63: 601-37.
9. Moestrup SK. The a2-macroglobulin receptor and epithelial glycoprotein-330: two giant receptors mediating endocytosis of multiple ligands. B B A 1994; 1197: 197-213.
10. Strickland DK, Kounnas MZ, Williams SE, Argraves WS. LDL receptor-related protein (LRP): a multiligand receptor. Fibrinolysis 1994; 8: 204-15.
11. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/a2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89: 7422-6.
12. Orth K, Willnow TE, Herz J, Gething MJ, Sambrook J. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator. J Biol Chem 1994; 269: 21117-22.
13. 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 1992; 89: 7427-31.
14. Nykjær A, Kjøller L, Cohen RL et al. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269: 25668-76.
15. Horn IR, van den Berg BMM, van der Meijden PZ, Pannekoek H, Zonneveld AJ. Molecular analysis of the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding. J Biol Chem 1997; 272: 13608-13.
16. Debrock S, Declerck PJ. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteases. FEBS Lett 1995; 376: 243-6.
17. Grobmyer SR, Kuo A, Orishimo M, Okada SS, Cines DB, Barnathan ES. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 1993; 268: 13291-300.
18. Camani C, Bachmann F, Kruithof EKO. The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells. J Biol Chem 1994; 269: 5770-5.
19. Camani C, Kruithof EKO. The role of the finger and growth factor domains in the clearance of tissue-type plasminogen activator by hepatocytes. J Biol Chem 1995; 270: 26053-6.
20. Moestrup SK, Holtet TL, Etzerodt M et al. Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats. J Biol Chem 1993; 268: 13691-6.
21. Willnow TE, Orth K, Herz J. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J Biol Chem 1994; 269: 15827-32.
22. Horn IR, Moestrup SK, van den Berg BMM, Pannekoek H, Nielsen MS, van Zonneveld AJ. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library. J Biol Chem 1995; 270: 11770-5.
23. Nykær A, Petersen CM, Moller B et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267: 14543-6.
24. 2-macroglobulin receptor (low density lipoprotein receptor-related protein). J Biol Chem 1991; 266: 14011-7.
25. Ehrlich H, Keijer J, Preissner KT, Klein Gebbink R, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30: 1021-8.
26. Ehrlich H, Klein Gebbink R, Keijer J, Pannekoek H. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 1992; 267: 11606-11.
27. Keijer J, Linders M, van Zonneveld AJ, Ehrlich H, de Boer JP, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activatores (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. Blood 1991; 78: 401-9.
28. Sancho E, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994; 224: 125-34.
29. van Meijer M, Roelofs Y, Neels J, Horrevoets AJG, van Zonneveld AJ. Selective screening of a large phage-display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator. J Biol Chem 1996; 271: 7423-8.
30. Schuck P, Minton AP. Kinetic analysis of biosensor data: elementary tests for self-consistency [see comments]. Trends in Biochemical Sciences 1996; 21: 458-60.
31. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
32. Stefansson S, Muhammad S, Lawrence DA. Clearance studies of PAI-1:protease complexes suggest that PAI-1 contains a cryptic LRP binding site. [Abstract] Fibrinolysis 1996; 10: 11.
33. Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996; 271: 8215-20.
34. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-A, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-40.
35. Shore JD, Day DE, Francis-Chmura AM et al. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 1995; 270: 5395-8.
36. Esko JD, Stewart TE, Taylor WH. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 1985; 82: 3197-201.
37. Chappell DA, Fry GL, Waknitz MA et al. Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans. J Biol Chem 1993; 268: 14168-75.
38. Mikhailenko I, Kounnas MZ, Strickland DK. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem 1995; 270: 9543-9.
39. 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996; 271: 6523-9.